Charles Crumpler
Interventional Cardiology · Longview, TXNPI 1609986165
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 243 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Edwards Lifesciences at 35.1% of the total. Reporting peaked in 2023 at $1,353 and has fallen 70.3% since, to $401 in 2025. That places this record below the midpoint for interventional cardiology clinicians in TX, where the typical reported total is $9,094.
Across 243 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Novartis$662
- Merck$316
- Johnson & Johnson$309
- E.r. Squibb & Sons, L.L.C.$226
- Pfizer$178
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,381100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 59 | $1,541 |
| Novartis | 55 | $662 |
| Merck | 19 | $316 |
| Johnson & Johnson | 22 | $309 |
| E.r. Squibb & Sons, L.L.C. | 15 | $226 |
| Pfizer | 5 | $178 |
| Abbott | 11 | $167 |
| Medtronic | 11 | $141 |
| Irhythm Technologies, Inc. | 6 | $119 |
| Gilead | 7 | $101 |
| Boston Scientific | 3 | $96 |
| Boehringer Ingelheim | 6 | $93 |
| Biotronik Inc. | 1 | $76 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $68 |
| Alnylam Pharmaceuticals Inc. | 2 | $66 |
| Amgen | 5 | $66 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Chiesi USA, Inc. | 2 | $30 |
| Cvrx, Inc. | 1 | $20 |
| Terumo Medical Corporation | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$120
- SAPIEN 3 Ultra RESILIA$118
How this compares
$4,395 in reported general payments places this provider in the 25th percentile of 686 interventional cardiology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 26 | $272 |
| Furosemide | 17 | $137 |
| Metoprolol Tartrate | 16 | $104 |
| Atorvastatin Calcium | 13 | $102 |
| Warfarin Sodium | 14 | $95 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Longview
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
- Peter MonteleoneKyle$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.